CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 279 enrolled
Drug / intervention
liraglutide +1 moredrug
Likely dose
liraglutide 1.8 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01620489
NCT01620489Phase 3Completed
CompareCT.gov

Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial

Novo Nordisk A/S·interventional·Posted Jun 15, 2012·Updated Mar 19, 2019

In Brief

A Phase 3 clinical trial evaluating liraglutide and placebo for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 279 participants across 97 sites in 6 countries.

Detailed Summary

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment. The trial medication will be add-on to the subject's stable pre-trial OAD and/or insulin regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesFrance, Poland, Russia, Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 15, 2012
Enrollment StartJun 14, 2012
Primary CompletionAug 20, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.0 years ago

Interventions

liraglutidedrug

1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.

placebodrug

Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.